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Abstract
A series of enantiopure isoxazolidines (3a–c) were synthesized by 1,3-dipolar cycload-
dition between a (−)-menthone-derived nitrone and various terminal alkenes. The
screened compounds were evaluated for their antioxidant activity by two in vitro
antioxidant assays, including β-carotene/linoleic acid bleaching, and inhibition of lipid
peroxidation (thiobarbituric acid reactive species, TBARS). The results revealed that
compound 3b (EC50 = 0.55 ± 0.09 mM) was the most potent antioxidant as compared to
the standard drug (EC50 = 2.73 ± 0.07 mM) using the TBARS assay. Furthermore, the
antimicrobial activity was assessed using disc diffusion and microdilution methods.
Among the synthesized compounds, 3c was found to be the most potent antimicrobial
agent as compared to the standard drug. Subsequently, the acute toxicity study has also
been carried out for the newly synthesized compounds and the experimental studies
revealed that all compounds were safe up to 500 mg/kg and no death of animals were
recorded. The cytotoxicity of these compounds was assessed by the MTT cell prolif-
eration assay against the continuous human cell lines HeLa and compound 3c (GI50 =
46.2 ± 1.2 μM) appeared to be more active than compound 3a (GI50 = 200 ± 2.8 μM)
and 3b (GI50 = 1400 ± 7.8 μM). Interestingly, all tested compounds displayed a good α-
amylase inhibitory activity in competitive manner with IC50 values ranging between
23.7 and 64.35 μM when compared to the standard drug acarbose (IC50 = 282.12 μM).
In addition, molecular docking studies were performed to understand the possible
binding and the interaction of the most active compounds to the α-amylase pocket.
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Heterocyclic compounds are the main class of cyclic organic compounds characterized by
containing at least one heteroatom, the most common heteroatoms being nitrogen, oxygen and
sulfur although other heterocyclic rings containing different heteroatoms are also known.
Heterocycles have their significance in the field of pharmacy and industry. The concept of
drug-like specie is very common in the field of medicinal chemistry; and the use of molecular
descriptors found in already known drugs, to help in the planning the design of new molecules,
is a broadly known strategy to exploit the chance of clinical success [1, 2].
Isoxazolidines are a class of powerful heterocycles [3], extensively used as precursors of
1,3-amino-alcohols or a various variety of natural compounds and derivatives [3], particularly
amino acids [4, 5], alkaloids [6] and amino sugars [7]. Isoxazolidines possess interesting
biological activities such as antioxidant [8, 9], antibacterial [9, 10], antifungal [11], antiretro-
viral [12] and antimycobacterial [13]. The 1,3-dipolar cycloaddition of nitrones and olefines is
one of the most useful reactions for the synthesis of heterocyclic isoxazolidine derivatives [14].
These 1,3-dipolar cycloaddition reactions exhibit a high potential since they form cycloadducts
with simultaneous creation of various chiral centers through highly stereocontrolled processes
[15].
Recently, Ghannay et al. [10] have described the synthesis, the antioxidant, and the
antimicrobial properties of enantiopure N-substituted pyrrolidin-2,5-dione derivatives obtained
by 1,3-dipolar cycloaddition between chiral nitrone and N-substituted maleimides. More
recently, Ghannay et al. [9] have reported the synthesis of novel enantiopure isoxazolidine
derivatives by 1,3-dipolar cycloaddition of substituted aryl allyl carbonates, with a (−)-
menthone-derived nitrone and the assessment of their in vitro antioxidant and antibacterial
activities.
In view of all these facts, we report herein the synthesis of enantiopure isoxazolidine
derivatives (3a–c) [4, 16] and the evaluation of some of their biological properties. The
antioxidant activity of the synthesized compounds was measured by different in vitro assays,
and antimicrobial activities were also evaluated by disc diffusion and microdilution methods.
The acute toxicity of the enantiopure isoxazolidine derivatives (3a–c) on Wistar rats was also
studied. The cytotoxic activity of compounds (3a–c) was tested using MTT cell proliferation
assay. Finally, in vitro inhibition of diabetes key enzyme (α-amylase) was evaluated and
molecular docking studies were performed to provide insights on the possible binding manner
and the interaction of these compounds with α-amylase.
Materials and Methods
Chemicals Reagents and Enzymes
Iron (II) sulfate (FeSO4), thiobarbituric acid (TBA), trichloroacetic acid (TCA), β-carotene,
linoleic acid, hydrochloric acid (HCl), sodium hydroxide (NaOH), acarbose, and porcine
pancreatic amylase (PPA) were purchased from Sigma-Aldrich. NaCl was obtained from
(Chemi Pharma, Tunisia). Hexane, chloroform, methanol, thin-layer chromatography (TLC)
performed on silica gel 60F254, and gel column chromatography performed with silica gel Si
60 (40–63 mm) were purchased from Merck (Darmstadt, Germany); and all other chemicals
used for the analyses were of analytical grade and were purchased from Sigma-Aldrich.
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General Procedure for the Synthesis of Novel Isoxazolidine Derivatives
Chiral nitrone 1 (0.84 mmol, 200 mg) and alkene (2.52 mmol) were dissolved in toluene
(10 mL) and heated together at reflux for 48 h with good stirring. TLC showed the complete
conversion of the chiral nitrone. The mixture was evaporated and the residue was purified by
flash chromatography (EtOAc–PE 3:7) to afford desired compound 3.
Evaluation of the Antioxidant Activity
β-Carotene Bleaching Assay
In this test, oxidation of linoleic acid produces several oxidation products, which attack the
chromophore of β-carotene, resulting in the bleaching of its characteristic color. However, the
existence of antioxidant inhibits the β-carotene bleaching by the formed linoleic acid oxidation
products. The capacity of the enantiopure isoxazolidine derivatives (3a–c) to prevent the
bleaching of β-carotene was carried out as previously described by Condelli et al. [17] with
a few modifications. In this assay, β-carotene (5 mg) was dissolved in 10 mL of chloroform
(HPLC grade). Thereafter, 750 μL of the obtained β-carotene solution, 33 μL of linoleic acid,
and 225 mg of Tween 40 were carefully mixed in round bottom flask. Then, the solvent was
removed using a rotavapor. To obtain an emulsion, 75 mL of water was added slowly to the
mixture and vigorously agitated. Aliquots (4 mL) of the emulsion (freshly prepared before
each experiment) were transferred into test tubes containing 200 μL of the enantiopure
isoxazolidine derivatives (3a–c) serially diluted in ethanol to produce a test range of 0.03 to
2 mg/mL. Thereafter, the test tubes were incubated in a water bath at 50 °C for 2 h together
with a negative control (blank) containing the same volume of ethanol instead of the sample.
The absorbance was measured for all samples at 470 nm, immediately (t = 0) and at after time
of 120 min, using a spectrophotometer against a blank consisting of an emulsion without β-
carotene. The percentage inhibition was calculated using the following formula:
I% ¼ AS120min−AC120min=AC0min−AC120minð Þ  100%
where AS120min is the absorbance of the sample at t = 120 min, AC12 0min is the absorbance of
the control at t = 120 min, and AC 0min is the absorbance of the control at t = 0 min.
Samples were read against a blank containing the emulsion of β-carotene/linoleic acid. The
isoxazolidine derivatives (3a–c) concentration (mg/mL) providing 50% inhibition (IC50) was
calculated from the graph plotting antioxidant activity against synthesized compounds con-
centration. Trolox was used as a positive standard. All the tests were carried out for three
sample replications and the results were averaged.
Thiobarbituric Acid Reactive Species Assay
The ability of isoxazolidine derivatives (3a–c) to inhibit the products of lipid peroxidation was
performed using TBARS quantification in homogenized sheep brain samples as described by
Bellé et al. [18] with some modifications. The brain of sheep was homogenized with a polytron
in ice-cold Tris-HCl buffer (20 mmol/L, pH 7.4) and was centrifuged at 3000 g during 10 min.
An aliquot (100 μL) of the recuperated supernatant was incubated with different concentra-
tions (0.03 to 2 mg/mL) of the samples solutions (200 μL) in the presence of 100 μL FeSO4
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(10 mmol/L) and 100 μL ascorbic acid (0.1 mmol/L) at 37 °C for 1 h. Thereafter, to stop the
reaction, 500 μL of TCA (28% w/v) followed by 380 μL of TBA, (2%, w/v) were added, and
the mixture was then heated at 80 °C for 20 min. After centrifugation at 3000 g for 10 min, to
remove the precipitated protein, the color intensity of the malondialdehyde (MDA)-TBA
complex in the supernatant was measured at 532 nm. The inhibition ratio (%) was calculated
using the following formula:
Inhibition ratio %ð Þ ¼ AbsC−AbsSð Þ=AbsC½   100%;




The target molecules were tested for antimicrobial activity against the following Gram-positive
bacteria: Staphylococcus aureus ATCC 25923, Staphylococcus epidermidis CIP, Bacillus
cereus ATCC 11778, Listeria monocytogenes CECT933, Enterococcus faecalis ATCC29212,
and Gram-negative bacteria: Vibrio parahaemolyticus ATCC 17802, Salmonella typhimurium
ATCC 1408, Escherichia coli ATCC 2592. On the other hand, the antifungal effect was tested
against four Candida strains (C. albicans ATCC 2019, C. krusei ATCC 6258, C. tropicalis 06-
085 and C. parapsilosis ATCC 22019).
Disc-Diffusion Assay
The antimicrobial activity was investigated as described by Vuddhakul et al. [19] with minor
modifications. In this assay, 10 μL from the microorganisms culture stock was activated on a tube
containing 9 mL of Mueller–Hinton (MH) broth (for bacteria) and Sabouraud (SB) chloramphen-
icol broth (for Candida), then incubated at 37 °C during 24 h. Cultures were then used for the
antimicrobial activity of the isoxazolidine derivatives (3a–c), and the optical density was adjusted
to 107 to 108 CFU/mL (0.1 at OD600 for bacteria and 0.4 at OD540 for Candida strains). The
inoculums of bacteria and fungus were streaked ontoMH and SB agar plates, respectively, using a
sterile cotton swab, as recommended by the CA-SFM EUCAST 2017. Sterile filter discs
(diameter 6 mm, Biolife Italy) were impregnated with 10 μL of the isoxazolidine derivatives
(3a–c) (2 mg/mL) and placed on the appropriate agar media. Ampicillin (10 mg/mL; 10 μL/disc)
and amphotericin B (10 mg/mL; 10 μL/disc) were served as positive standards.
After 24 h of culture (37 °C), the diameter of the growth inhibition zone (IZ) was measured
using a flat rule. Each experiment was carried out in triplicate and the mean value of the
inhibition zones was registered. The results were expressed in terms of inhibition zone (IZ) of
growth around each disc in millimeters as low activity (1–6 mm), moderate activity (7–
10 mm), high activity (11–15 mm), and very high activity (12–20 mm) [20].
Micro-Well Determination of MICs and MBCs/MFCs
The minimal inhibition concentrations (MICs) and the minimal bactericidal/fungicidal con-
centrations (MBCs/MFCs) values were deduced for all microbial strains as described by
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Snoussi et al. [21] with some few modifications. The bacterial/fungal inoculums were prepared
from 12-h broth cultures and suspensions and spectrophotometrically adjusted to 107 CFU/mL.
The derivatives (3a–c) were first dissolved in ethanol (10%) and then serial twofold dilutions
were made in a concentration range of 0.0018 to 2 mg/mL into 5 mL sterile glass tubes
containing nutrient broth. Firstly, 95 μL of nutrient broth was dispersed in each well of plates.
An aliquot of 100 μL from the stock solutions of each tested compound was added into the
wells. Finally, 5 μL from each microbial suspension was added to all the wells. The first well
containing 195 μL of nutrient broth (Mueller–Hinton broth or Sabouraud chloramphenicol
broth) without isoxazolidine derivatives (3a–c) and 5 μL of the inoculum corresponds to the
negative control. The final volume in each well was 200 μL. The plates were incubated during
24 h at 37 °C. The MIC was defined as the lowest concentration of the derivatives (3a–c) able
to inhibit the growth of the microorganisms, so no visible changes were detected in the broth
medium. The MBC/MFC ratio corresponds to the highest dilution of each sample, which
exhibited clear fluid and an absence of visible growth.
Experimental Animals
Wistar rats, weighing 160–180 g were recuperated from Pasteur Institute (Tunis, Tunisia). The
animals were allowed free access to standard diet and water ad libitum. They were housed in
cages and left for 2 days for acclimatization to animal room, maintained under controlled
condition with an alternating 12 h light (L)/12 h dark (D) cycle (D/L/12:12 photoperiod at 22
± 2 °C). Before the day of administration, the animals were fasted overnight with free access to
water. The animals were manipulated based on the guidelines of the Tunisian Society for the
Care and Use of Laboratory Animals (ATSAL), and the protocol for the rat studies was
approved by Institutional Animal Ethics of local Committee for Animal Care and Use.
Acute Toxicity Studies
The oral acute toxicity of the isoxazolidine derivatives (3a–c) was carried out and the LD50
value was determined. The laboratory rats were subjected to a fasting overnight prior to
administration of the compounds. Two groups (n = 6) were treated by oral administration of
derivatives (3a–c) at different doses (200 and 500 mg/kg). The compounds (3a–c) were diluted
in DMSO (maximum final concentration of 4%) and orally administered (per gavage). For the
untreated group (negative control), distilled water was used with dose of 10 mL/kg. The
positive control group received DMSO 4%. After the treatment period and for the first 4 h, the
animals were carefully controlled for any toxic effect. Later, animals were observed during
14 days for any toxic effect or mortality [22]. The clinical observation was effected once a day
to control the mortality, ill health or reaction to treatment, such as changes in fur and skin, eyes,
behavior pattern, salivation, sleep, tremors, diarrhea, and coma.
On the sacrifice day, blood was withdrawn from all rats under urethane anesthesia.
Thereafter, the blood in the plain test tube was allowed to stand for a minimum of 3 h to
complete clotting. To recover the serum, the upper phase was recuperated and centrifuged at
4000 rpm at 4 °C for 10 min. The serums were then kept at −20 °C until analysis for clinical
biochemistry measurements using the enzymatic methods on an Integra 400 automaton (Roche
Diagnostics, Mannheim, Germany). The clinical biochemistry values determination was for
liver profile (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)). Renal
profile parameters measured were urea, creatinine, and CRP.
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Cytotoxic Activity
The cytotoxic effect of the derivatives (3a–c) was tested using MTT cell proliferation assay as
described by Ben Mansour et al. [23]. Briefly, the continuous human cell lines HeLa (epithelial
cervical cancer cell line) (ATCC, Manassas, VA, USA) were grown on different concentrations
of the derivatives (3a–c). Forty-eight hours later, MTTwas added. After 4 h of incubation, the
formazan salts were dissolved and the OD was measured (570 nm). The results were expressed
as GI50 values, concentration that inhibited 50% of the net cell growth.
In Vitro α-Amylase Inhibition Assay and Kinetics Study
The porcine pancreatic α-amylase (PAA) activity was assessed using the dinitrosalicylic acid
(DNS) method as described by Miller [24]. The reaction mixture contained 0.5 mL of
appropriately diluted enzyme (2 U/mL) and 0.5 mL of buffer A (100 mmol/L MOPS pH 7;
3 mmol/L CaCl2 and 10 mmol/L NaCl) containing 0.5% (w/v) of soluble starch. Maltose
solution was used as reference to calculate the amylase activity.
To evaluate the inhibitory effects of the derivative compounds (3a–c) on α-amylase, PPA
was preincubated at room temperature (1 h) with different compounds concentrations (5 to
200 μM). The reaction medium contained 20 μL of the extract and 20 μL of PPA. After
incubation at 37 °C for 10 min, 1 mL of 3,5-dinitrosalicylic acid was added for the reaction
mixture. At last, after incubation in a boiling water bath for 5 min, 10 mL of distilled water
were added, and finally the absorbance was measured at 540 nm. A control tube was prepared
similarly to the medium of the inhibition test but without compounds. For this assay, acarbose
was used as a positive control. The PPA residual activity (RA %) was calculated as follows:
RA %ð Þ ¼ A=B 100
where, A corresponds to the activity with inhibitor and B to the activity without inhibitor. The
IC50 values were calculated from plots of concentration of synthesized compounds versus
percentage inhibition curves. The result is expressed as IC50 (mg/mL), which corresponds to
the compound concentration required to inhibit 50% of PPA activity. All tests were carried out
in triplicate.
For the kinetic study, the reaction mixture was performed as described above, except that
the substrate concentrations increased from 0.31 to 10 mM and in the presence of different
concentrations of derivatives (3a–c). The results were used to construct Lineweaver–Burk
plots to determine the type of inhibition, apparent Michaelis-Menten constant (Kmapp) and
maximum velocity (Vmax) values. The inhibition constant (KI) were determined plotting Kmapp
vs. inhibitor concentration.
Molecular Docking
Molecular docking has recently been established as an efficient technique for high
throughput in silico screening of compounds’ libraries. Molecular docking specifies the
best positioning of a tested compound that interacts with the target protein, predicting the
structure of a ligand within the constraints of a receptor binding site [25]. The chemo-
informatics and computational chemistry increasingly plays a significant role in the
initial examination of potential drug [26].
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In this work, to explain the interactions between the derivatives (3a–c) and pancreatic α-
amylase, an in silico molecular docking study was established. To perform the docking studies,
a PPA crystal structure was selected and obtained from the Protein Data Bank (PDB entry:
1HX0). The protein structure was prepared for docking by removing all waters and
acarviosine-glucose that were co-crystallized with the structure. AutoDockTools1.5.2 (ADT)
was then used to assign polar hydrogens, add Gasteiger charges, and save the protein structure
in PDBQT file format [27]. A docking grid was selected using ADT in order to encompass the
ligand binding site completely. The X,Y,Z grid center coordinates selected were 34.0, 20.0, and
53.3, respectively; and the X,Y,Z grid dimensions used were 30 by 30 by 30 Angstroms. The
2D structures of the studied derivative compounds (3a–c) were drawn using the ACD/
ChemSketch Freeware 12.0 software. VegaZZ software was then used to perform 2D to 3D
conversion and to save the structures in PDB file format [28]. Finally, ADT was used to
convert PDB to PDBQT file format. All docking simulations were performed using AutoDock
Vina software [29], using an exhaustiveness parameter of 32. Docking conformation analysis
and image preparation were performed using PyMOL software [30].
Statistical Analysis
The means and standard error (SEM) of data were calculated from independent experiments.
Data analysis was performed using one-way ANOVA analyses followed by multi-range post
hoc of Dunnett’s test (comparison of control group with other groups). Statistical analyses
were realized using GraphPad Prism and InStat softwares (GraphPad Software, La Jolla,
USA). Graph Pad Prism was also used to fit sigmoid curves models. All statistical assays
were two-tailed and (p < 0.05) or less was then considered significant.
Results and Discussion
Chemistry
The chiral nitrone 1 has been prepared from the (−)-menthone as reported earlier by Altenbach
et al. [31]. The 1,3-dipolar cycloaddition of 1 with alkenes 2a–c in refluxing toluene for 48 h
afforded enantiopure isoxazolidines 3a–c in good yields (Scheme 1 and Table 1). The
stereoselectivity resulting from the approach of alkenes 2b–c on the less hindered face of
the spirocyclic nitrone 1 has been discussed [4, 16]. The regioselectivity of the 1,3-dipolar
cycloaddition reaction between 1 and 2a has been reported [5, 31].
Evaluation of Antioxidant Activity
It is obviously known that compounds with antioxidant properties could be expected to
prevent some chronic human diseases and can lead to potentially effective drugs. To the best
of our literature search, the synthesized enantiopure isoxazolidine derivatives are rarely
reported for their antioxidant property [32].
In this work, the antioxidant activity of compounds 3a–c was investigated by β-carotene
bleaching and TBARS assays. The results were expressed as EC50 values, with lower EC50
values indicating higher antioxidant activity.
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As depicted in Table 2, using the β-carotene bleaching assay, the EC50 values for the
different compounds (3a–c) ranged from 0.73 ± 0.08 to 1.67 ± 0.12 mM. The stronger antiox-
idant activity was obtained with compound 3b which is about 3.6 times lower than that of the
specific inhibitor Trolox (EC50 = 0.2 ± 0.01 mM) followed by 3a and in lower degree 3c.
Furthermore, our results show that the ability to inhibit the products of lipid peroxidation
(TBARS assay) was very noticeable for all derivatives compounds (3a–c) than that obtained
with the standard drug (Trolox). Results presented in Table 2 revealed that the EC50 value of
compound 3b was 0.55 ± 0.09 mM which is fivefold lower compared to Trolox (2.73 ±
0.07 mM).
According to the two antioxidant assays, we can notice essentially that the compound 3b
(R1:CH2OH, R2: CH2OH) was the most active than other compounds. This interesting
antioxidant activity may be related to the presence of two electron-donating groups (-CH2OH)
as side chains. This observation is in accordance with the previous works [10, 32, 33] which
confirm the interference of side chains of compounds on their biological properties.
Antimicrobial Activity
Data on the antimicrobial activity of novel enantiopure isoxazolidine derivatives (3a–c) are
reported in this work for the first time and are given as inhibition zone (IZ) diameters, MICs,
MBCs, and MFCs (Tables 3 and 4). The antimicrobial activities of the target molecules were
carried out using the agar diffusion and the microdilution methods on 12 test microorganisms,
including 8 bacteria (5 Gram-positive and 3 Gram-negative) and 4 yeasts.
Our results show that the compounds were active against all the microbial strains, but in
different degrees (Table 3). With the compound 3a, the IZ varied from 13.0 ± 0.57 to 22.33 ±
0.57 mm, for bacterial strains, and from 7.0 ± 0.15 to 17.33 ± 1.15 mm for yeast strains. On the
Scheme 1 Synthesis of enantiopure isoxazolidines 3a–c
Table 1 Synthesis of enantiopure isoxazolidines (3a–c)
Entry Compounds R1 R2
1 3a CH2OH H
2 3b CH2OH CH2OH
3 3c CH2Cl CH2Cl
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other hand, with the compound 3b, the values of the IZ varied between 10.0 ± 0.57 to 15.0 ±
1.15 mm, for bacterial strains, and 7.0 ± 0.15 to 20.33 ± 0.57 mm for yeast strains. Finally, as
listed in Table 3, we notice especially that the compound 3c (R1:CH2Cl, R2: CH2Cl) appears
the most active with the highest inhibition zones for the bacterial as well as the yeast strains.
When using this compound (3c), E. coli ATCC 2592 appears the most sensitive bacteria, with
IZ value of 26.0 ± 1.15 mm which is about twofold higher than that measured with standard
antibiotic (ampicillin). Similarly, Candida krusei ATCC 6258 was the most sensitive yeast,
with IZ value of 24.66 ± 1.01 mm which is about 2.2-fold higher than that measured with
standard antibiotic (amphotericin B).
After the disk diffusion analyses, the active compounds were analyzed using an MIC assay
to determine the lowest concentration able to inhibit visible bacterial growth. The MIC values
listed in Table 4 revealed that all compounds 3a–c had promising antimicrobial profiles against
all tested bacteria strains with MICs (0.06–0.25 mg/mL) close to that observed for ampicillin
used as standard antibiotic.
Table 2 Antioxidant activity of isoxazolidine derivatives (3a–c)
(EC50, mM)
Compounds β-carotene bleaching TBARS
(3a) 1.35 ± 0.11 0.81 ± 0.11
(3b) 0.73 ± 0.08 0.55 ± 0.09
(3c) 1.67 ± 0.12 1.40 ± 0.14
Trolox 0.2 ± 0.01 2.73 ± 0.07
Mean ± SD, n = 3
EC50, compound concentration corresponding to 50% of antioxidant activity
Table 3 Antimicrobial activity of isoxazolidine derivatives (3a–c)
Microorganisms Inhibition zones diameter (mm)a
Bacteria strains (3a) (3b) (3c) Ampicillinb
Staphylococcus aureus ATCC 25923 22.33 ± 0.57 14.00 ± 0.1 24.00 ± 1.15 26.66 ± 0,57
Bacillus cereus ATCC 11778 15.00 ± 0.57 15.00 ± 1.15 17.00 ± 0.57 26.00 ± 1.00
Staphylococcus epidermidis CIP 19.00 ± 1.15 12.00 ± 0.57 20.00 ± 0.0 22.67 ± 0.57
Enterococcus faecalis ATCC 29212 17.00 ± 1.00 14.00 ± 1.00 21.00 ± 1.00 13.67 ± 0.57
Listeria monocytogenes CECT 933 13.00 ± 0.57 14.00 ± 0.57 14.00 ± 0.57 12.66 ± 0.57
Escherichia coli ATCC 2592 22.00 ± 1.15 13.00 ± 0.57 24.66 ± 1.01 11.67 ± 0.57
Vibrio parahaemolyticus ATCC 17802 18.00 ± 1.15 10.00 ± 0.57 20.00 ± 1.15 13.33 ± 0.57
Salmonella typhimurium ATCC 1408 16.00 ± 1.15 13.00 ± 1.15 15.00 ± 1.00 17.67 ± 1.15
Yeast strains (3a) (3b) (3c) Amphotericin B
Candida albicans ATCC 2019 7.00 ± 0.15 7.00 ± 0.15 14.00 ± 0.57 12.66 ± 0.57
Candida krusei ATCC 6258 17.33 ± 1.15 20.33 ± 0.57 26.00 ± 1.15 12.00 ± 0.00
Candida tropicalis 06–085 12.33 ± 0.57 14.33 ± 0.57 14.33 ± 0.57 1.00 ± 0.00
Candida parapsilosis ATCC 22019 15.33 ± 0.57 16.66 ± 0.57 21.66 ± 0.57 10.33 ± 0.57
The data are expressed as mean ± SD (n = 3)
a Diameter of inhibition zones of compound including diameter of well 6 mm
bAmpicillin or amphotericin B was used as standard antibiotic at a concentration of 10 mg/mL
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Thereafter, MBC or MFC which is the lowest concentration of compound or antibi-
otics that completely kills inoculated bacteria or fungi, respectively, was also determined.
As depicted in Table 4, these values varied from 0.25 to 1 mg/mL for bacteria or yeasts
and they are lower than those recorded with ampicillin or amphotericin particularly
against E. coli ATCC 2592, V. parahaemolyticus ATCC 17802 and Candida tropicalis
06-085.
The difference in antimicrobial behavior of the tested compounds (3a–c) could be
ascribed to the variation of susceptibility of the tested strains which may be related to
their surface cells permeability to the tested derivatives. Also, this variation may be
related to the solubility of these compounds in water [34, 35] and impermeability of the
microorganism cells or differences between the ribosomes of microbial cells [36].
Acute Toxicity Studies
Physical Observation and Mortality
According to our toxicity study, no mortality of administered rats and no toxic effects
were observed during the experimental period (14 days). Furthermore, the physical
observation indicated that none of them exhibited signs of toxic effects, such as changes
on skin, behavior pattern, salivation, tremors, diarrhea, sleep, and coma. Interestingly, no
death also was recorded in both control and treated rats, suggesting that the LD50 for
chronic oral dosing with each of compounds was much higher than 500 mg/kg. Accord-
ing to the obtained LD50 value, it can be suggested that the isoxazolidine derivatives
(3a–c) should be considered as practically non-toxic in acute ingestion.








Bacteria strains MICa MBCb MICa MBCb MICa MBCb MICa MBCb/
MFCc
Staphylococcus aureus ATCC 25923 0.125 0.25 0.25 1.00 0.25 1.00 0.25 0.40
Bacillus cereus ATCC 11778 0.125 0.25 0.06 0.25 0.25 1.00 0.25 0.40
Staphylococcus epidermidis CIP 0.125 0.25 0.125 0.50 0.125 0.50 0.011 12.00
Enterococcus faecalis ATCC 29212 0.125 0.25 0.125 0.50 0.125 0.50 0.023 0.093
Listeria monocytogenes CECT 933 0.125 0.25 0.125 0.50 0.125 0.50 0.023 0.093
Escherichia coli ATCC 2592 0.125 0.25 0.25 1.00 0.25 1.00 0.023 3.00
Salmonella typhimurium ATCC 1408 0.125 0.25 0.125 0.50 0.25 1.00 0.023 0.093
Vibrio parahaemolyticus ATCC 17802 0.25 0.50 0.125 0.50 0.25 0.50 0.011 3.00
Yeast strains MICa MFCc MICa MFCc MICa MFCc Amphotericin B
Candida albicans ATCC 2019 0.125 0.50 0.25 0.50 0.25 1.00 0.024 0.781
Candida krusei ATCC 6258 0.125 0.50 0.25 0.50 0.50 1.00 0.09 0.195
Candida tropicalis 06–085 0.25 1.00 0.25 1.00 0.25 1.00 0.39 6.25
Candida parapsilosis ATCC 22019 0.50 1.00 0.125 0.25 0.50 1.00 0.195 0.39
aMinimal inhibitory concentration (mg/mL)
bMinimal bactericidal concentration (mg/mL)
cMinimal fungicidal concentration (mg/mL)
Applied Biochemistry and Biotechnology
Clinical Biochemistry
The clinical biochemistry (ALT, AST, urea, creatinine and CRP) results are summarized in
Table 5. Interestingly, the clinical biochemistry parameters values were not significantly
different (p > 0.05) as compared to the control group. It is well known that transaminases
(AST and ALT) are used as excellent indicators of liver function [37, 38]. It is also demon-
strated that the lesion in the parenchymal cells of liver may increase the level of both
transaminases in the blood. In addition, any increase in the level of AST in serum can be
considered as a first sign of cell damage. We can deduce that the absence of significant
differences in ALT and AST activities of the administered groups compared the control
suggests that the chronic administration of compounds (3a–c) did not alter the hepatocytes
and therefore the metabolism of the rats.
On the other hand, the level of creatinine and urea is well known as good indicators of the
renal function [38]. Any damage in functional nephrons is generally marked by the increase of
urea or creatinine levels [39]. Therefore, the results found in this study suggest that compounds
(3a–c) did not also alter the renal function.
Cytotoxic Activity
Cancer is a major health concern all around the world. Progresses in prevention and treatment
of cancer have decreased the health rate, but the number of new diagnoses continues to
increase. Therefore, new and more efficient anticancer agents are required to battle different
cancer diseases. Furthermore, according to the various clinical studies [40, 41], it has been
shown that compounds having the ability to block or suppress the proliferation of cancer cell
by the induction of apoptotic cell death are considered as strong anticancer agents.
In our case, antiproliferative activity of isoxazolidine derivatives (3a–c) was evaluated
in vitro by the estimation of cell growth effects on human cell lines HeLa (epithelial cervical
Table 5 Effect of isoxazolidine derivatives (3a–c) on biochemical parameters of liver and kidney in rats











Group I Negative control
(distilled water)
118.42 ± 4.44 52.82 ± 2.45 7.02 ± 1.22 18.54 ± 1.12 47.28 ± 2.02
Group II Positive control
(DMSO 4%)
119.22 ± 4.12 51.06 ± 3.12 7.12 ± 1.02 17.88 ± 1.92 46.66 ± 4.22
Group III Compound (3a)
(200 mg/kg)
119.12 ± 4.81 50.22 ± 5.27 6.83 ± 0.71 18.46 ± 1.06 47.33 ± 5.04
Compound (3b)
(200 mg/kg)
120.45 ± 5.11 51.13 ± 4.27 6.74 ± 0.82 18.26 ± 1.12 47.13 ± 4.64
Compound (3c)
(200 mg/kg)
119.85 ± 4.66 52.02 ± 3.27 6.88 ± 1.08 17.91 ± 1.36 47.02 ± 3.68
Group IV Compound (3a)
(500 mg/kg)
118.80 ± 5.72 50.63 ± 4.50 7.01 ± 0.98 17.98 ± 2.02 47.19 ± 6.82
Compound (3b)
(500 mg/kg)
119.52 ± 4.37 51.10 ± 5.14 6.85 ± 0.94 18.50 ± 1.73 46.586.51
Compound (3c)
(500 mg/kg)
119.88 ± 4.80 51.76 ± 4.26 6.96 ± 1.08 17.98 ± 1.82 47.33 ± 3.62
ALT alanine aminotransferase, AST aspartate aminotransferase, CRP: C-reactive protein
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cancer cell line). The results obtained are expressed as GI50, which correspond to the
concentration required to reach 50% of growth inhibition.
Ours results show that all derivatives have important toxicity to the cell type tested when
compared to other studies [42, 43]. When comparing the GI50 values of compounds 3a–c,
compound 3c (46.2 ± 1.2 μM) appeared to be more active against HeLa human cell lines than
compounds 3a (200 ± 2.8 μM) and 3b (1400 ± 7.8 μM).
α-Amylase Inhibition Assay and Kinetics Study
Carbohydrates are the main component of daily diet and play a key role in energy supply. The
constituents of dietary carbohydrates should be cleaved into monosaccharides by the combined
action of the two enzymes, α-amylase and α-glucosidase. The obtained monosaccharides can
be absorbed from the lumen of intestine and thereafter circulated into the blood [44]. The
inhibition of one or both enzymes (α-amylase and α-glucosidase) slows down the carbohy-
drates digestion and leads to decrease in blood glucose level and therefore it could be
considered as a promising therapeutic way for the treatment of diabetes [45, 46].
All synthetic compounds (3a–c) were evaluated for their in vitro porcine pancreatic α-
amylase inhibitory activities at different concentrations and IC50 values were calculated
(Fig. 1). A dose-dependent effect was observed upon increasing the concentrations of each
compound and the maximum of inhibition (90%) was recorded with the compound 3c at only
165 μM. The results showed that all compounds exhibited potent inhibitory activity with IC50
values ranging between 23.7 and 64.35 μM (Table 6) when compared to the standard drug
acarbose (IC50 = 282.12 μM).
The inhibition type of the isoxazolidine derivatives (3a–c) was determined using
Lineweaver–Burk (double-reciprocal) plots as shown in Fig. 2a–c. For each compound, all
lines had nearly the same y-intercept, while they had different slopes and x-intercepts,
indicating that the type of inhibition was competitive. As shown by several researchers, in
competitive inhibition, the inhibitor (compounds) and the substrate mutually and exclusively
bind to the free enzyme, and therefore the inhibitor competes with the substrate for the free
enzyme [47]. In fact, the competitive inhibition results of the three derivatives (3a–c) revealed
that they all could occupy the active pocket of α-amylase that bound to starch, thereby
competitively inhibiting α-amylase.
Furthermore, the inhibition constant (KI) for each inhibitor was determined by plotting
Kmapp against inhibitor concentration. As reported in Table 6, compound 3c (R1:CH2Cl, R2:
CH2Cl) was the most effective inhibitor of α-amylase followed by compound 3a (R1:CH2OH,
R2: H) and compound 3b (R1:CH2OH, R2: CH2OH) with KI values of 160.17, 574.32, and
858.9 μM, respectively.
Structure-Based Docking Studies
To better understand the molecular basis of compounds (3a–c) porcine pancreatic α-amylase
(PPA) inhibition activity, docking simulations using AutoDock Vina software were carried out
against a known PPA protein structure (PDB code: 1HX0). In accordance with the experi-
mental PPA inhibition results, compound 3c presented the lowest predicted binding energy
(ΔG) value of −8,3 Kcal/mol, while compounds 3a and 3b presented higher ΔG values of,
respectively, −6.2 and − 6.3 Kcal/mol. Since the predicted docking scores relate well with the
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experimental results, we set out to analyze in more detail the predicted docking conformation
of compound 3c.
Figure 3a displays the PPA structure used in the presented docking studies (PDB: 1HX0).
In green color, we can observe acarviosine-glucose, the co-crystallized ligand that is bound to
PPA catalytic site. Acarviosine-glucose is the smallest molecule of the trestatin family that
inhibits PPA and yet is not hydrolyzed by the enzyme [48]. Superimposed to acarviosine-
glucose is, in cyan color, the predicted docked conformation of compound 3c. We can observe
that compound 3c fits nicely in the catalytic site of PPA. Figure 3b shows compound 3c
predicted docked conformation in more detail. It is possible to observe that both chloride
atoms and the carbonyl group oxygen present in compound 3c structure are facing the solvent,
probably being stabilized by hydrogen bonds, while the rings are positioned nicely in the
different sub-pockets that comprise the complete PPA catalytic site. Taken together, the
predicted binding energy and docked conformation of compound 3c make a strong statement
that the obtained docked conformation is probably the actual binding mode of compound 3c.
Conclusion
In summary, we have reported the synthesis of enantiopure isoxazolidine derivatives
(3a–c) by 1,3-dipolar cycloaddition between a (−)-menthone-derived nitrone and





















Fig. 1 Residual α-amylase activity at various concentrations of isoxazolidine derivatives (3a–c). Each point is
the average value of three independent experiments
Table 6 Inhibitory effect of isoxazolidine derivatives (3a–c) on α-amylase activity
Compound IC50 (μM) KI (μM) Inhibition mode
(3a) 25.56 574.32 Competitive
(3b) 64.35 858.9 Competitive
(3c) 23.7 160.17 Competitive
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various alkenes. Some biological activities of the compounds were evaluated. The
synthesized compounds display promising antimicrobial and antioxidant activities com-
pared to the standard drugs. Regarding the antioxidant activities, all of the synthesized
compounds were active and compounds 3b (R1:CH2OH, R2: CH2OH) presented the
best results in TBAS assay. Among these compounds, 3c (R1:CH2Cl, R2: CH2Cl)
showed notable antimicrobial activity with MIC and MBC values in the range of
0.25 to 1.0 mg/mL against all the tested strains. According to our results, the
isoxazolidine derivatives (3a–c) should be considered as practically non-toxic in acute
ingestion since any mortality of treated rats and no toxic effects were observed during
the study period. All compounds exhibited superior α-amylase inhibitory activity in the
range of IC50 = 23.7 and 64.35 μM as compared to standard acarbose (IC50 =
282.12 μM). Molecular docking studies were carried out to better understand the
molecular interaction of compounds with the active site of α-amylase. Among these
compounds, 3c may potentially be developed as a new α-amylase inhibitor for the
treatment of type 2 diabetes.
Overall, although the number of derivatives in this work is reduced, the results of biological
activities are very promising. Therefore, in the future, we attempt to the synthesis of the new
isoxazolidine derivatives by systematic modification around our compounds with potent
activities to produce drugs with higher therapeutic effect.
Fig. 2 Lineweaver–Burk plots of α-amylase inhibition at different substrate [S] concentrations in absence or
presence of various concentrations of compound 3a (a), compound 3b (b), and compound 3c (c). Each point is
the average value of three independent experiments
a b
Fig. 3 Representation of PPA structure with docking conformation of compound 3c. a Surface representation of
PPA with the co-crystallized acarviosine-glucose molecule (green color, wire representation) and the docked
conformation of compound 3c (cyan color, sticks and balls representation). b Detailed representation of
compound 3c predicted docked conformation
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